Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Pituitary Neoplasms × farletuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 2 Pituitary Neoplasms 1 Peritoneal Neoplasms 1 Fallopian Tube Neoplasms 1 Adenocarcinoma of Lung 1

Interventions

pasireotide 3 lutetium Lu 177 dotatate 1 farletuzumab 1 Thyrotropin-Releasing Hormone 1 Temozolomide 1 TBR-760 1 Rosiglitazone 1 Nivolumab 1 Microarray Analysis 1 Ipilimumab 1 DNA Methylation 1 Cabergoline 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01203618 2013-11-04

Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

Morphotek

Phase 2 Withdrawn

Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡